Efficacy and safety of isatuximab plus bortezomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma ineligible/with no immediate intent for autologous stem cell transplantation.

"Competing interests EMO: Honoraria – Amgen, BMS/Celgene, GSK, Janssen, MSD, Oncopeptides, Sanofi, Takeda. AP: Honoraria – AbbVie, Amgen, BMS/Celgene, GSK, Janssen, Sanofi, Takeda. PB: nothing to disclose. JFSM: Honoraria – AbbVie, Amgen, BMS, Celgene, GSK, Haemalogix, Janssen, Karyopharm, MSD, Novartis, Regeneron, Roche, Sanofi, SecuraBio, Takeda. IWB: nothing to disclose. LK: Honoraria – AbbVie, Amgen, Celgene, Janssen, Sanofi, Takeda; Advisory Role: Amgen, Celgene, GSK, Janssen, Takeda. JM-L: Honoraria – Janssen, BMS, Incyte, Roche, Novartis, Amgen, Adaptive, Gilead, Sanofi. WP: nothing to disclose. SB: Honoraria – Janssen, Takeda, Amgen, Sanofi, Celgene, Oncopeptides, GSK, Bristol Myers Squibb. MM: nothing to disclose. M-VM: Honoraria – Sanofi. PR-O: Honoraria – Celgene-BMS, Janssen, Sanofi, AbbVie, GSK, Oncopeptides, Kite Pharma, Amgen. LD, SM, and TF are employed by Sanofi and may hold stock and/or stock options in the company Sanofi. NLR and MG are contractors for Sanofi on behalf of Altran and Excelya. PM: Consulting – AbbVie, Amgen, Celgene, Jansen, Oncopeptides, Sanofi; Honoraria – AbbVie, Amgen, Celgene, Janssen, Oncopeptides, Sanofi; Advisory Role – AbbVie, Amgen, Celgene, Janssen, Oncopeptides, Sanofi."

"Funding This study was sponsored by Sanofi."